These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 35689472)

  • 1. Cost-effectiveness of osimertinib versus placebo in resected EGFR-mutated non-small cell lung cancer in China.
    Zhou X; Du J; Xu G; Chen C; Zheng B; Chen J
    Cancer Med; 2022 Dec; 11(23):4449-4456. PubMed ID: 35689472
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Modeling the Cost-Effectiveness of Adjuvant Osimertinib for Patients with Resected EGFR-mutant Non-Small Cell Lung Cancer.
    Lemmon CA; Zabor EC; Pennell NA
    Oncologist; 2022 May; 27(5):407-413. PubMed ID: 35285487
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cost-effectiveness of Osimertinib vs Docetaxel-bevacizumab in Third-line Treatment in EGFR T790M Resistance Mutation Advanced Non-Small Cell Lung Cancer in China.
    Rui M; Li H
    Clin Ther; 2020 Nov; 42(11):2159-2170.e6. PubMed ID: 33028495
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cost-effectiveness of Osimertinib as First-line Treatment and Sequential Therapy for EGFR Mutation-positive Non-small Cell Lung Cancer in China.
    Cai H; Zhang L; Li N; Chen S; Zheng B; Yang J; Weng L; Liu MB
    Clin Ther; 2019 Feb; 41(2):280-290. PubMed ID: 30639208
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cost-effectiveness of Osimertinib as a Second-line Treatment in Patients With EGFR-mutated Advanced Non-Small Cell Lung Cancer in China.
    Guan H; Liu G; Xie F; Sheng Y; Shi L
    Clin Ther; 2019 Nov; 41(11):2308-2320.e11. PubMed ID: 31607559
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Economic evaluation of adjuvant therapy with osimertinib in patients with early-stage non-small cell lung cancer and mutated EGFR.
    Vila Pérez A; Alegre-Del Rey EJ; Fénix-Caballero S; Špacírová Z; Rosado Varela P; Olry de Labry Lima A
    Support Care Cancer; 2023 Dec; 32(1):67. PubMed ID: 38150163
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Osimertinib in the treatment of resected EGFR-mutated non-small cell lung cancer: a cost-effectiveness analysis in the United States.
    Huo G; Song Y; Liu W; Cao X; Chen P
    Front Pharmacol; 2024; 15():1300183. PubMed ID: 38606181
    [No Abstract]   [Full Text] [Related]  

  • 8. Cost-Effectiveness of Osimertinib in Treating Newly Diagnosed, Advanced EGFR-Mutation-Positive Non-Small Cell Lung Cancer.
    Wu B; Gu X; Zhang Q; Xie F
    Oncologist; 2019 Mar; 24(3):349-357. PubMed ID: 30257889
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cost-effectiveness of osimertinib in the UK for advanced EGFR-T790M non-small cell lung cancer.
    Bertranou E; Bodnar C; Dansk V; Greystoke A; Large S; Dyer M
    J Med Econ; 2018 Feb; 21(2):113-121. PubMed ID: 28880737
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cost-effectiveness analysis of first-line treatments for advanced epidermal growth factor receptor-mutant non-small cell lung cancer patients.
    Li WQ; Li LY; Chai J; Cui JW
    Cancer Med; 2021 Mar; 10(6):1964-1974. PubMed ID: 33626238
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Economic analysis of osimertinib in previously untreated EGFR-mutant advanced non-small cell lung cancer in Canada.
    Ezeife DA; Kirk V; Chew DS; Nixon NA; Lee R; Le LW; Chan KK; Leighl NB
    Lung Cancer; 2018 Nov; 125():1-7. PubMed ID: 30429004
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cost-effectiveness of osimertinib versus standard EGFR-TKI as first-line treatment for EGFR-mutated advanced non-small-cell lung cancer in China.
    Shu Y; Ding Y; He X; Liu Y; Wu P; Zhang Q
    Front Pharmacol; 2022; 13():920479. PubMed ID: 36204237
    [No Abstract]   [Full Text] [Related]  

  • 13. Cost-effectiveness of osimertinib versus standard EGFR-TKI as first-line treatment for locally advanced or metastatic EGFR mutation-positive non-small cell lung cancer in Australia.
    Khoo T; Gao L
    Expert Rev Pharmacoecon Outcomes Res; 2021 Jun; 21(3):415-423. PubMed ID: 33151783
    [No Abstract]   [Full Text] [Related]  

  • 14. Osimertinib versus platinum-pemetrexed in patients with previously treated EGFR T790M advanced non-small cell lung cancer: An updated AURA3 trial-based cost-effectiveness analysis.
    Shi Y; Pei R; Liu S
    Front Oncol; 2022; 12():833773. PubMed ID: 36324594
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cost-Effectiveness of Osimertinib for EGFR Mutation-Positive Non-Small Cell Lung Cancer after Progression following First-Line EGFR TKI Therapy.
    Wu B; Gu X; Zhang Q
    J Thorac Oncol; 2018 Feb; 13(2):184-193. PubMed ID: 29101057
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cost-effectiveness analysis of osimertinib for first-line treatment of locally advanced or metastatic EGFR mutation positive non-small cell lung cancer in Singapore.
    Aziz MIA; Foo WYX; Toh CK; Lim WT; Ng K
    J Med Econ; 2020 Nov; 23(11):1330-1339. PubMed ID: 32886557
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cost-effectiveness analysis of different sequences of osimertinib administration for epidermal growth factor receptor-mutated non-small-cell lung cancer.
    Li W; Qian L; Li W; Chen X; He H; Tian H; Zhao Y; Wang X; Cui J
    Exp Ther Med; 2021 Apr; 21(4):343. PubMed ID: 33732316
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cost-effectiveness analysis of adding ramucirumab to the first-line erlotinib treatment for untreated EGFR-mutated metastatic non-small cell lung cancer in China.
    Liu Q; Luo X; Peng L; Yi L; Wan X; Zeng X; Tan C
    BMJ Open; 2020 Nov; 10(11):e040691. PubMed ID: 33243806
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluation of Cost-Effectiveness of Adjuvant Osimertinib in Patients with Resected EGFR Mutation-Positive Non-small Cell Lung Cancer.
    Verhoek A; Cheema P; Melosky B; Samson B; Shepherd FA; de Marinis F; John T; Wu YL; Heeg B; Van Dalfsen N; Bracke B; Miranda M; Shaw S; Moldaver D
    Pharmacoecon Open; 2023 May; 7(3):455-467. PubMed ID: 36811822
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluation of osimertinib for advanced non-small cell lung cancer with leptomeningeal metastases: a cost-effectiveness and budget impact analysis.
    Luo S; Weng X; Lin S; Huang X; Huang L; Zhou W; Guo X; Xu X
    Int J Clin Pharm; 2022 Feb; 44(1):192-200. PubMed ID: 34633624
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.